Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janice Smith

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Cancer Research|December 3, 2008
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastomaMichael D Hogarty, Murray D Norris, Kimberly Davis, et al.
The New England Journal of Medicine|November 15, 2023
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's DiseaseRandall J Bateman, Janice Smith, Michael C Donohue, et al.
Journal of the National Cancer Institute|July 30, 2011
ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug effluxMichelle J Henderson, Michelle Haber, Antonio Porro, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2013
A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitorsSue J Sohn, Kathy Barrett, Anne Van Abbema, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 25, 2020
CNVs cause autosomal recessive genetic diseases with or without involvement of SNV/indelsBo Yuan, Lei Wang, Pengfei Liu, et al.
Cell|February 25, 2017
An Organismal CNV Mutator Phenotype Restricted to Early Human DevelopmentPengfei Liu, Bo Yuan, Claudia M B Carvalho, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Cancer Research|December 3, 2008
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastomaMichael D Hogarty, Murray D Norris, Kimberly Davis, et al.
The New England Journal of Medicine|November 15, 2023
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's DiseaseRandall J Bateman, Janice Smith, Michael C Donohue, et al.
Journal of the National Cancer Institute|July 30, 2011
ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug effluxMichelle J Henderson, Michelle Haber, Antonio Porro, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2013
A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitorsSue J Sohn, Kathy Barrett, Anne Van Abbema, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 25, 2020
CNVs cause autosomal recessive genetic diseases with or without involvement of SNV/indelsBo Yuan, Lei Wang, Pengfei Liu, et al.
Cell|February 25, 2017
An Organismal CNV Mutator Phenotype Restricted to Early Human DevelopmentPengfei Liu, Bo Yuan, Claudia M B Carvalho, et al.
Pageof 6